About
Technology
Issues
FAQ
Search
Scientometrics
Impact Factor
Discipline Ranks
h
-index
g
-index
Articles
Citations
Article Citations
Citation Distribution
Overviews
Top Institutions
Top Schools
Top Authors
Prolific Authors
Top Articles
Citing Bodies
Top Citing Authors
Top Citing Institutions
Top Citing Schools
Top Citing Journals
Top Citing Disciplines
exaly
›
Journals
›
Pharmacogenomics Journal
›
top-articles
Pharmacogenomics Journal
2.6
(top 20%)
impact factor
1.3K
(top 20%)
papers
49.7K
(top 10%)
citations
97
(top 5%)
h
-index
2.6
(top 20%)
impact factor
1.5K
all documents
52.4K
doc citations
151
(top 5%)
g
-index
Top Articles
#
Title
Journal
Year
Citations
1
Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity
Pharmacogenomics Journal
2005
962
2
UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity
Pharmacogenomics Journal
2002
664
3
Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer's disease
Pharmacogenomics Journal
2006
649
4
Thymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy
Pharmacogenomics Journal
2001
545
5
Common VKORC1 and GGCX polymorphisms associated with warfarin dose
Pharmacogenomics Journal
2005
434
6
Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs
Pharmacogenomics Journal
2011
412
7
Pharmacogenomics of human UDP-glucuronosyltransferase enzymes
Pharmacogenomics Journal
2003
386
8
The VNTR polymorphism of the human dopamine transporter (DAT1) gene affects gene expression
Pharmacogenomics Journal
2001
383
9
Metagenomic sequencing of the human gut microbiome before and after bariatric surgery in obese patients with type 2 diabetes: correlation with inflammatory and metabolic parameters
Pharmacogenomics Journal
2013
380
10
Pharmacokinetics of codeine and its metabolite morphine in ultra-rapid metabolizers due to CYP2D6 duplication
Pharmacogenomics Journal
2007
379
11
A marker for Stevens-Johnson syndrome …: ethnicity matters
Pharmacogenomics Journal
2006
367
12
A TOMM40 variable-length polymorphism predicts the age of late-onset Alzheimer's disease
Pharmacogenomics Journal
2010
351
13
Integrating genotype and phenotype information: an overview of the PharmGKB project
Pharmacogenomics Journal
2001
340
14
HIBAG—HLA genotype imputation with attribute bagging
Pharmacogenomics Journal
2014
339
15
Genome-wide pharmacogenetic investigation of a hepatic adverse event without clinical signs of immunopathology suggests an underlying immune pathogenesis
Pharmacogenomics Journal
2008
335
16
Pharmacogenetics of warfarin: current status and future challenges
Pharmacogenomics Journal
2007
290
17
A comparison of batch effect removal methods for enhancement of prediction performance using MAQC-II microarray gene expression data
Pharmacogenomics Journal
2010
249
18
ABCB1 genotype and PGP expression, function and therapeutic drug response: a critical review and recommendations for future research
Pharmacogenomics Journal
2007
247
19
Single nucleotide polymorphism genotyping: biochemistry, protocol, cost and throughput
Pharmacogenomics Journal
2003
226
20
Specific and overlapping functions of the nuclear hormone receptors CAR and PXR in xenobiotic response
Pharmacogenomics Journal
2002
221
21
Pharmacogenomics of drug-metabolizing enzymes: a recent update on clinical implications and endogenous effects
Pharmacogenomics Journal
2013
218
22
Comparison of different isolation techniques prior gene expression profiling of blood derived cells: impact on physiological responses, on overall expression and the role of different cell types
Pharmacogenomics Journal
2004
213
23
Role of polymorphic human CYP2B6 in cyclophosphamide bioactivation
Pharmacogenomics Journal
2003
200
24
HLA-A*31:01 and different types of carbamazepine-induced severe cutaneous adverse reactions: an international study and meta-analysis
Pharmacogenomics Journal
2014
199
25
Genetic variation in the organic cation transporter 1 is associated with metformin response in patients with diabetes mellitus
Pharmacogenomics Journal
2009
198
26
The human dopamine D4 receptor repeat sequences modulate expression
Pharmacogenomics Journal
2003
194
27
A common P-glycoprotein polymorphism is associated with nortriptyline-induced postural hypotension in patients treated for major depression
Pharmacogenomics Journal
2002
190
28
An association study of 43 SNPs in 16 candidate genes with atorvastatin response
Pharmacogenomics Journal
2005
190
29
Sulfation through the looking glass—recent advances in sulfotransferase research for the curious
Pharmacogenomics Journal
2002
189
30
The functional mu opioid receptor (OPRM1) Asn40Asp variant predicts short-term response to nicotine replacement therapy in a clinical trial
Pharmacogenomics Journal
2004
188
31
Genetic predictors of response to antidepressants in the GENDEP project
Pharmacogenomics Journal
2009
188
32
Pharmacogenetics and the concept of individualized medicine
Pharmacogenomics Journal
2006
187
33
Warfarin sensitivity related to CYP2C9, CYP3A5, ABCB1 (MDR1) and other factors
Pharmacogenomics Journal
2004
181
34
Cost-effectiveness of pharmacogenetic-guided treatment: are we there yet?
Pharmacogenomics Journal
2017
173
35
Ticlopidine-induced hepatotoxicity is associated with specific human leukocyte antigen genomic subtypes in Japanese patients: a preliminary case–control study
Pharmacogenomics Journal
2008
171
36
Genetic polymorphisms and the efficacy and toxicity of cisplatin-based chemotherapy in ovarian cancer patients
Pharmacogenomics Journal
2010
169
37
Pharmacogenetics of the arylamine N-acetyltransferases
Pharmacogenomics Journal
2002
167
38
Response to fluoxetine and serotonin 1A receptor (C-1019G) polymorphism in Taiwan Chinese major depressive disorder
Pharmacogenomics Journal
2006
165
39
Molecular classification of psoriasis disease-associated genes through pharmacogenomic expression profiling
Pharmacogenomics Journal
2001
163
40
A whole-genome association study of major determinants for allopurinol-related Stevens–Johnson syndrome and toxic epidermal necrolysis in Japanese patients
Pharmacogenomics Journal
2013
160
41
Differential effect of the rs4149056 variant in SLCO1B1 on myopathy associated with simvastatin and atorvastatin
Pharmacogenomics Journal
2012
158
42
Role of polymorphisms in MTHFR and MTHFD1 genes in the outcome of childhood acute lymphoblastic leukemia
Pharmacogenomics Journal
2004
152
43
Cytochrome P450 2C19*2 polymorphism and cardiovascular recurrences in patients taking clopidogrel: a meta-analysis
Pharmacogenomics Journal
2011
152
44
The expanding role of BDNF: a therapeutic target for Alzheimer's disease?
Pharmacogenomics Journal
2006
150
45
Clinical implications of pharmacogenomics of statin treatment
Pharmacogenomics Journal
2006
150
46
Influence of polymorphisms of ABCB1 and ABCC2 on mRNA and protein expression in normal and cancerous kidney cortex
Pharmacogenomics Journal
2007
148
47
Tamoxifen metabolism predicts drug concentrations and outcome in premenopausal patients with early breast cancer
Pharmacogenomics Journal
2015
148
48
Antipsychotic drugs activate SREBP-regulated expression of lipid biosynthetic genes in cultured human glioma cells: a novel mechanism of action?
Pharmacogenomics Journal
2005
143
49
Sequence variations in the UDP-glucuronosyltransferase 2B7 (UGT2B7) gene: identification of 10 novel single nucleotide polymorphisms (SNPs) and analysis of their relevance to morphine glucuronidation in cancer patients
Pharmacogenomics Journal
2003
141
50
The influence of SLCO1B1 (OATP1B1) gene polymorphisms on response to statin therapy
Pharmacogenomics Journal
2010
141
site/software ©
exaly
; All materials licenced under
CC by-SA
.